margetuximab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
chimeric origin 5434 1350624-75-7

Description:

MoleculeDescription

Molfile

Synonyms:

  • margetuximab
  • margetuximab-cmkb
  • margenza
  • MGAH22
Margetuximab-cmkb, a HER2/neu receptor antagonist, is a chimeric Fc-engineered IgG1 kappa monoclonal antibody. It binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC).
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 16, 2020 FDA MACROGENICS INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FD06 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000020008 HER2/Neu/cerbB2 Antagonists
FDA EPC N0000175661 HER2/neu Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Metastatic human epidermal growth factor 2 positive carcinoma of breast indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Receptor tyrosine-protein kinase erbB-2 Kinase ANTAGONIST Kd 8.55 DRUG LABEL DRUG LABEL
Low affinity immunoglobulin gamma Fc region receptor III-A Membrane receptor ANTAGONIST Kd 7.05 DRUG LABEL DRUG LABEL

External reference:

IDSource
D10446 KEGG_DRUG
K911R84KEW UNII
C4053695 UMLSCUI
CHEMBL2364649 ChEMBL_ID
DB14967 DRUGBANK_ID
8686 IUPHAR_LIGAND_ID
018597 NDDF
1144474002 SNOMEDCT_US
1144506004 SNOMEDCT_US
4040181 VANDF
4040182 VANDF
2473850 RXNORM
341786 MMSL
39092 MMSL
d09695 MMSL
C000617981 MESH_SUPPLEMENTAL_RECORD_UI
9799 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MARGENZA HUMAN PRESCRIPTION DRUG LABEL 1 74527-022 INJECTION, SOLUTION, CONCENTRATE 25 mg INTRAVENOUS BLA 29 sections
MARGENZA HUMAN PRESCRIPTION DRUG LABEL 1 74527-022 INJECTION, SOLUTION, CONCENTRATE 25 mg INTRAVENOUS BLA 29 sections